Key Takeaways
- Revenue down, profit up: Consolidated revenue fell 6% QoQ to INR458 crores as product prices corrected, but EBITDA rose 6% to INR85 crores and PAT rose 10% to INR48 crores because raw material costs corrected in parallel.
- Xanthine margin compression is the core story: The segment's revenue share dropped from 56% to 50% as sales prices fell below last year's levels, even though volumes increased; management is compensating by expanding tonnage and backward-integrating a key imported raw material.
- Capacity build-out is accelerating: A debottlenecking added 1,000 tons of Xanthine capacity, the Atali greenfield broke ground, and backward integration for Xanthine's main raw material is on track for Q2 completion, aiming to eliminate China dependence.
- CDMO/CMO is the growth bet: 16 products commercialized and 12 under development, with the business potentially reaching 10% or more of overall revenue this year; a dedicated R&D center has been set up post-demerger to chase this opportunity.
- What to watch next quarter: Whether the backward-integration project delivers on time and starts showing margin benefit, the pace of API plant utilization ramp-up in H2, and whether Xanthine pricing stabilizes or keeps eroding the mix.
Xanthine: Margin Pressure and the Volume Offset
- Price decline drove the mix shift: Xanthine volumes increased but overall sales prices are lower than last year, so the segment's revenue share fell from 56-58% to 50%. The high-base effect from two years of elevated Xanthine margins makes the compression look steeper than it might otherwise.
- Capacity is near-full: The plant operates at 90-95% of nameplate capacity, so absolute contribution cannot grow without further expansion. The recent debottlenecking added 1,000 metric tons, and utilization of that new capacity is expected to reach 90% in H2 of this fiscal year.
- Market position provides headroom: The company is the largest domestic Xanthine player but captures only 15-20% of the market; smaller competitors are not significant. Management sees enough opportunity to grow share without a demand breakthrough.
- End-use flexibility buffers demand risk: Xanthine products are interchangeable between pharma, food, and cosmetic applications. If pharma demand weakens, product is pushed into food and cosmetic channels, and vice versa, giving the portfolio a natural hedge.
- No China dumping, just normal competition: China has always supplied roughly 80% of the world market and continues to do so; the product is export-driven and management sees no evidence of dumping into India.
Management: “We are utilizing our capacity to almost 90%. So unless we increase the capacity, the absolute number of the contribution won’t grow. So we are planning to look at opportunities to further debottleneck. So that overall market we are only capturing 15% to 20%. So there is enough opportunity which is available for us to grow.”
Backward Integration and Capacity Expansion
- Xanthine raw material independence: One project estimated for completion in Q2 of this fiscal year will manufacture the main raw material for Xanthine products, which is currently imported. This makes the company completely independent of China in this chemistry and may deliver savings or margin improvement.
- Debottlenecking completed: Xanthine nameplate capacity has been expanded from 4,000 to 5,000 tons per annum through a debottlenecking exercise that added reactors.
- Atali greenfield gaining momentum: Work on the greenfield project at Atali, Gujarat accelerated this quarter. Phase 1 is expected to complete in H2 FY25 and will focus largely on intermediates and CMO/CDMO projects in the intermediate segment; API CMO will stay at the Tarapur API plant. The full land area will be utilized over the next 5 to 7 years.
- API block ramp-up: An additional block commissioned in the API manufacturing plant during FY23 is expected to begin its utilization ramp-up from H2 of this fiscal year, with full ramp-up typically taking around two years.
- Tarapur ramp-up: The Tarapur project is expected to ramp up over the next one to one-and-a-half years.
Rashesh Gogri: "One of the projects estimated to be completed in Q2 of this year is to manufacture the main raw material for Xanthine products, which is being currently imported. This will make us completely independent of China in this chemistry."
CDMO/CMO: The Growth Engine
- Pipeline is building: 16 products have been commercialized and 12 products are under development in the CDMO/CMO segment. The business has potential to reach 10% or more of overall revenue this year, though this depends on customer programs and commercialization timelines.
- Phase 2 and upwards focus: The company operates in scale-ups and commercialization, not early-stage discovery or "mad chemistry." It targets products with commercialization potential, working from Phase 2 onwards.
- Post-demerger independence: The demerger has given the pharma business more independence to pursue credible R&D and CDMO/CMO business. A new R&D center specifically catering to the CDMO/CMO segment has been started.
- Shared assets create quarterly lumpiness: CDMO and API numbers fluctuate quarter-to-quarter because API intermediates and CMO/CDMO business use the same shared assets; the mix depends on which products and orders ship in a given quarter.
- Longer-term ambition: Per an analyst's math, CDMO/CMO contribution could move from 6% to 15% over the next three years; management expressed positivity about the trajectory but did not confirm the 15% target.
Rashesh Gogri: "In CDMO, CMO space, generally we like to operate in phase 2 and upwards... we are not working on mad chemistry, we are working on scale ups and commercialization, the products which have potential of commercialization."
API and Intermediates: Regulated-Market Play
- Therapy area footprint: The company operates in anti-hypertensive, anti-asthma (steroids), anti-cancer, CNS, and now anti-diabetic segments, choosing lifestyle drugs that are high-value and low-volume, focused on regulated markets.
- Intermediates serve dual purpose: Intermediates manufactured are used for captive consumption and also sold to large Indian pharma companies (Dr. Reddy's, Cipla, Zydus, Mylan) as an alternative to Chinese intermediates, supported by USFDA-approved facilities.
- Utilization is plant-specific: Intermediate plants run at roughly 80% plus/minus 5%, while the API plant is lower due to its recent commissioning. Peak revenue from existing facilities is not a fixed number because the same asset can produce products ranging from INR5,000/kg to INR50,000/kg depending on the mix.
- Product development engine: The R&D program typically takes up to 40 products for development and ends up doing 8 to 10 APIs, with the balance in the intermediate space. The total basket going ahead is 150 products.
- US market presence: Around 12 to 15 products are actively sold in the US market, though management acknowledged the need to quantify the exact number. A US trading subsidiary (Piyush) is currently shared with Aarti Industries but will eventually be separated.
Rashesh Gogri: "And typically we like to do more value-added products as far as possible and do lesser and lesser of the lower value product, low margin product. So that is how we try to manage overall product mix."
Margins and Financial Levers
- EBITDA grew despite revenue decline: Revenue fell 6% on lower product prices, but raw material costs corrected in parallel, so absolute EBITDA rose 6% to INR85 crores. The absolute EBITDA number has not de-grown.
- Sustainable margin band: Management sees a sustainable overall EBITDA margin near 20%, plus or minus 2 percentage points, for the company as a whole. Segment-level margins were not disclosed.
- Asset turns target: The company is currently at roughly 1.5x asset turns and wants to expand that number closer to 2x.
- R&D spend: Running at INR35 to INR40 crores per quarter.
- Inventory to liquidate: Inventories that have increased will be sold in the coming quarter, which should support near-term revenue.
- Export proportion rising: The proportion of exports is expected to keep growing over the next two to three years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Backward integration project | Manufacture main Xanthine raw material in-house, eliminating China dependence | Q2 of this fiscal year |
| Atali greenfield Phase 1 | Complete first phase, focused on intermediates and CMO/CDMO | H2 FY25 |
| API plant utilization ramp-up | Ramp-up of the newly commissioned API block to begin | H2 of this fiscal year |
| Tarapur project ramp-up | Full ramp-up of Tarapur facility | Next 1 to 1.5 years |
| Overall EBITDA margin | Sustainable range of 20% plus/minus 2 percentage points | Ongoing |
| Top-line and EBITDA growth | 12% to 17% growth across all three segments | Ongoing |
| CDMO/CMO contribution | Reach 10% or more of overall business | This fiscal year |
| Asset turns | Improve from ~1.5x toward 2x | No fixed date |
| Xanthine capacity utilization | Newly added 1,000 tons to reach 90% utilization | H2 of this fiscal year |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Consolidated revenue | ₹458 cr, declined 6% YoY |
| Consolidated EBITDA | ₹85 cr, increased 6% YoY |
| Consolidated profit after tax | ₹48 cr, higher by 10% QoQ |
| EBITDA margin guidance (medium-term) | 12% to 17% |
| Sustainable EBITDA margin range | ~20%, plus or minus 2% |
| Xanthine revenue share (standalone) | ~50%, down from 55% in FY23 |
| API and intermediates revenue share | ~43% |
| CDMO and CMO revenue share | 6%, potential to reach 10% or more this year |
| Xanthine capacity | 5,000 tons per annum, expanded from 4,000 via debottlenecking |
| Xanthine capacity utilization | ~90% |
| Xanthine global market share | 15% to 20% |
| CDMO and CMO products commercialized | 16 products, with 12 under development |
| API products commercialized | 50 APIs, around 12 to 15 actively sold in the US |
| R&D expense run-rate | ₹35 to ₹40 cr per quarter |
| Atali Greenfield project capex | ₹350 cr (first phase), overall capex of ₹500 cr |